Long-lasting Thrombocytopenia after Transient Pancytopenia Induced by Short-Term Concomitant Radiotherapy and Temozolomide

  • Aleksandar Stepanović Institute for Oncology and Radiology of Serbia
  • Marina Nikitović nstitute for Oncology and Radiology of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia
  • Andrija Bogdanović Hematology Clinic, Clinical Center of Serbia, Belgrade, Serbia; Neurosurgery Clinic, Clinical Center of Serbia, Belgrade, Serbia
  • Danica Grujičić Faculty of Medicine, University of Belgrade, Belgrade, Serbia; Neurosurgery Clinic, Clinical Center of Serbia, Belgrade, Serbia
DOI: https://doi.org/10.12890/2020_001785

Keywords

Glioblastoma, temozolomide, pancytopenia, thrombocytopenia

Abstract

We describe long-lasting and incompletely resolved thrombocytopenia after transient profound pancytopenia in a 62-year-old female patient with glioblastoma after short-term radiotherapy with temozolomide. Pancytopenia was present for more than 4 weeks and thrombocytopenia for more than 6 months, without platelet recovery to normal levels.

VIEW THE ENTIRE ARTICLE

References

  • Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med2005;352(10):997–1003.

  • Altinoz MA, Elmaci I, Bolukbasi FH, Ekmekci CG, Yenmis G, Sari R, et al. MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case. J Chemother 2017;29(4):238–244.

  • Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987–996.

  • Chamberlain MC. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 2010;10(10):1537–1544.

  • Armstrong TS, Cao Y, Scheurer ME, Vera-Bolaños E, Manning R, Okcu MF, et al. Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol 2009;11(6):825–832.

  • Vandraas K, Tjønnfjord GE, Johannesen TB, Brandal P. Persistent bone marrow depression following short-term treatment with temozolomide. BMJ Case Rep 2016;2016:bcr2016215797.

  • Tinchon A, Oberndorfer S, Marosi C, Gleiss A, Geroldinger A, Sax C, et al. Haematological toxicity of valproic acid compared to levetiracetam in patients with glioblastoma multiforme undergoing concomitant radio-chemotherapy: a retrospective cohort study. J Neurol 2015;262:179–186.

  • Lew J, Berenberg J. Metronidazole caused profound drug-induced immune thrombocytopenia. Clin Case Rep 2017;6(1):206–208.

    • Published: 2020-07-07

    Issue: Vol 7 No 10 (view)

    Section: Articles

    How to cite:
    1.
    Stepanović A, Nikitović M, Bogdanović A, Grujičić D. Long-lasting Thrombocytopenia after Transient Pancytopenia Induced by Short-Term Concomitant Radiotherapy and Temozolomide. EJCRIM 2020;7 doi:10.12890/2020_001785.